Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Dermira (DERM) today and set a price target of $20. The company’s shares closed yesterday at $12.76.
Chen wrote:
“DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.6% and a 47.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Dermira is a Strong Buy with an average price target of $21.43.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.48 and a one-year low of $6.00. Currently, Dermira has an average volume of 2.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.
